FAAH1 (L14B8) Mouse mAb





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 60	Source/Isotype: Mouse IgG1	UniProt ID: #O00519	Entrez-Gene Id: 2166		
Product Usage Information	2	Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sensitivity FAAH1 (L14B8) Mouse mAb detects endogeno				genous levels of total FA	AH1 protein.			
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val42 of human FAAH1 protein.						
Background		Endogenous cannabinoids have been implicated in addictive behaviors and drug abuse (1). Fatty-acid amide hydrolase 1 (FAAH1) is a plasma membrane-bound hydrolase that converts oleamide to oleic acid (2). This hydrolase also converts the cannabinoid anandamide, the endogenous ligand for the CB1 cannabinoid receptor, to arachidonic acid, suggesting a role in fatty-acid amide inactivation (2). Mice lacking FAAH1 have significantly higher levels of anandamide in the brain and show decreased sensitivity to pain, further indicating a role for FAAH1 in the regulation of endocannabinoid signaling <i>in vivo</i> (3). FAAH1 null mice also demonstrate an increased preference for alcohol and an increased voluntary uptake of alcohol as compared to wild-type mice, indicating a role of FAAH1 in modulating addictive behaviors (1).						
Background R	eferences	1. Blednov, Y.A. et al. (2007) <i>Neuropsychopharmacology</i> 32, 1570-82. 2. Cravatt, B.F. et al. (1996) <i>Nature</i> 384, 83-7. 3. Cravatt, B.F. et al. (2001) <i>Proc Natl Acad Sci USA</i> 98, 9371-6.						
Species Reacti	vity	Species reactivity is de	termined by testin	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot I	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ley	W: Western Blotting IP: Immunoprecipitation						
Cross-Reactivi	ty Key	H: Human M: Mouse						
Trademarks and Patents		Cell Signaling Technolo	ogy is a trademark	of Cell Signaling Techno	logy, Inc.			
		All other trademarks a more information.	re the property of	their respective owners.	Visit cellsignal.com	/trademarks for		
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		approved, cleared, or l purpose. Customer sh any manner that confl Customer as the end-u diagnostic, prophylact	icensed by the FDA all not use any Pro icts with its labelin user and solely for ic or therapeutic p	se Only or a similar labe or other regulatory for duct for any diagnostic o g statement. Products so research and developme urposes, or any purchas e, requires a separate lio	eign or domestic er or therapeutic purp- old or licensed by C ent uses. Any use of e of Product for res	ntity, for any ose, or otherwise in ST are provided for Product for ale (alone or as a		

sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.